European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months ...

DUBLIN and BRIDGEWATER, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced financial and operational results for the second quarter of 2025.